Hexarelin protects the heart not just through growth hormone release but via a dedicated cardiac receptor (CD36), making it a more stable and potent alternative to natural ghrelin.
Dual receptor mechanismHexarelin acts through both GHSR (hormonal) and CD36 (cardiac) receptors, providing direct cardioprotection
What the researchers found
Hexarelin, a synthetic growth hormone-releasing peptide, has direct cardiovascular effects beyond growth hormone release. It activates both the ghrelin receptor (GHSR) in the brain and a specific cardiac receptor called CD36, which mediates its cardioprotective effects. Compared to the natural hormone ghrelin, hexarelin is more chemically stable and functionally more potent.
The review summarizes evidence that hexarelin can protect the heart through direct actions on cardiac and vascular tissue, independent of its growth hormone-stimulating properties.
Why it matters
Growth hormone-releasing peptides have been studied primarily for their hormonal effects, but hexarelin's direct cardiac actions through the CD36 receptor represent a distinct therapeutic mechanism. If these cardioprotective effects can be harnessed clinically, hexarelin could serve as a targeted cardiac peptide therapy, particularly for conditions where growth hormone effects are unwanted.
The numbers in context
2 receptors: GHSR (brain) and CD36 (cardiac) · More stable than ghrelin · More potent than ghrelin · Direct cardiac and vascular actions
How the study worked
Concise narrative review summarizing preclinical and mechanistic evidence for hexarelin's cardiovascular actions, including receptor binding studies, cardiac protection experiments, and comparisons with natural ghrelin.
Who was studied
Not applicable (review of preclinical and mechanistic studies)
What this study cannot tell us
As a brief narrative review, it does not comprehensively evaluate all available evidence or assess study quality. Most evidence is preclinical. Clinical cardiovascular studies of hexarelin are limited. The review is from 2014 and newer evidence may have emerged.
How to read the evidence
This is a narrative review of mostly preclinical evidence. While it identifies an interesting mechanism (CD36-mediated cardioprotection), human cardiovascular data for hexarelin remains limited.
When this study was published
Published in 2014, this review provides foundational context for hexarelin's cardiovascular pharmacology. The CD36 receptor and growth hormone secretagogue peptide field has continued to evolve since publication.
The bigger picture
The discovery that growth hormone secretagogue peptides have direct cardiovascular effects through non-GHSR receptors expanded the field beyond endocrinology. Hexarelin and related peptides are now being studied as cardiac therapeutics, and the CD36 receptor pathway represents a novel pharmacological target for heart protection that is distinct from conventional cardiovascular drug mechanisms.
Questions still open
- Can hexarelin analogs be designed that selectively activate CD36 without triggering growth hormone release?
- Would hexarelin be beneficial in human heart failure or after myocardial infarction?
- How does hexarelin's cardioprotection compare to established cardiovascular drugs in preclinical head-to-head studies?
Common questions
What is hexarelin?
How does hexarelin protect the heart?
Read the original research
The cardiovascular action of hexarelin.
Journal of geriatric cardiology : JGC, 11(3), 253-8
Citation
Mao, Yuanjie; Tokudome, Takeshi; Kishimoto, Ichiro. (2014). The cardiovascular action of hexarelin.. Journal of geriatric cardiology : JGC, 11(3), 253-8. https://doi.org/10.11909/j.issn.1671-5411.2014.03.007